Chronic hepatitis C virus (HCV) infection is found in about 3% of the world population and has become one of the major causes of liver cirrhosis and hepatocellular carcinoma. Treatment for HCV infection is widely available in places where it is affordable, and a variety of pharmacogenetic analyses have already suggested that differential response to HCV therapy can be related to coding and noncoding (promoter/regulatory) sequence variations in the human genome. However, most studies have been compromised by small sample size, nonrepresentative subject selection, and/or low-resolution genotyping. Systematic investigations of larger, representative populations will be essential for the generation of consensus data to guide experimental and clinical research.
HETEROGENEITY IN RESPONSE TO HCV THERAPY
Treatment of HCV infection is suboptimal: many patients do not respond to or tolerate the typical full-dose combination therapy (FCT ¼ 48-week-long injection of interferon alpha 2b plus daily oral dose of ribavirin) or modified FCT (MFCT ¼ peginterferon a2b plus ribavirin). In particular, fewer than half of patients with genotype 1 HCV infection can achieve sustained viral suppression (below level of detection by polymerase chain reaction) for at least 24 weeks after completing FCT or MFCT.
1,2 Likewise, only a minority of treated patients exhibit other forms of therapeutic success characterized by normalization of alanine aminotransferase (ALT) concentration and improvement in histological grading of liver biopsy.
Major predictors of sustained response (SR) include age, body mass index (BMI ¼ body weight/height 2 expressed as kg/m 2 ), duration of HCV infection, expression of IFN receptor genes IFNAR1 and IFNAR2, pretreatment HCV RNA level, first, and second-phase viral decay kinetics, and HCV genotype. Thus, the majority of SR patients are under 40 years old and have normal BMI and low baseline HCV RNA level, along with non-1 HCV genotypes and accelerated viral decay in the early periods of therapy. [2] [3] [4] [5] In addition to the various factors enumerated above, documentation of higher SR rate in European Americans than African Americans has highlighted the ethnic differences, most likely due to genetic heterogeneity or increased occurrence of HCV genotype 1 in black people. Pharmacogenetic studies should be useful in elucidating such individual and ethnic disparities in response to HCV therapy. 6, 7 The main expectation is that recognition of reliable genetic markers will substantially improve intervention strategies through individualization of therapeutic regimens, thereby reducing costs and avoiding debilitating complications. These studies also hold the promise of identifying additional molecular mechanisms that can be targeted for new, more effective interventions. The À88G/G genotype defined by a single-nucleotide polymorphism (SNP) in the MX1 promoter was found more frequently in the NR group among Japanese (n ¼ 115) 8 and British patients (n ¼ 171).
CONFIRMED
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A related MX1 genotype, -123G/G has shown a similar effect due to tight linkage disequilibrium (LD) between À88G and À123G. 9 In the British study, MX1 À88G/G was also predictive of unfavorable outcome in untreated infection: it was overrepresented in patients without selflimiting HCV. 7 The same study dismissed another MX1 SNP (À545A4G) as a significant factor while revealing some trends for additional SNPs in the promoter or 3 0 UTR of two other genes (OAS1 and PKR) involved in the IFNinduced antiviral pathways ( Figure 1 ).
The MX1 (MxA) À88G4T SNP is located within a region with close sequence similarity to consensus IFNstimulated response element. Substitution of À88T for À88G increases the sequence homology further, 8 and experimental analyses indicate that cloned MX1 promoter construct carrying À88T and À123A has a fourfold higher transcriptional activity compared with the À123G and À88G construct. 9 Other compelling evidence suggests that SR patients do have increased MX1 mRNA production and elevated MX1 protein level during treatment. 10 Thus, the pharmacogenetic and experimental findings are internally and externally consistent with a convincing causal relationship.
ADDITIONAL LEADS
As with immunogenetic studies of natural HCV infection, 11 other immune response genes are also frequently implicated as pharmacogenetically relevant. In those analyses of more than a single SNP or mutation in more than 100 patients, preliminary genetic markers include HLA and related variants on chromosome 6, 12,13 homozygosity for an extended haplotype (HHE) along the CCR2 to CCR5 loci on chromosome 3, 14 as well as cytokine gene and related polymorphisms mapped to various locations. [6] [7] [8] For example, HLA-DRB1*07 was associated with the NR phenotype in treated French (n ¼ 170), 12 while Japanese patients (n ¼ 175) with the LMP7 variant that changes amino acid 49Gln to 49Lys were more likely to be sustained responders (SRs). 13 In CTLA4, the 49G variant on the (À381)C-49G haplotype has been associated with SR in one study of European Americans (n ¼ 158). 15 For genotypes resolved by similar techniques in multiple studies, inconsistent results have been reported: the IL10 haplotype ATA (i.e., À1082A, À819 T, and À592A) was initially associated with SR status in European Americans (n ¼ 104), 6 but later work suggested that homozygosity of the reciprocal IL10 haplotype GCC (À1082G, À819C, and À592C) had the same effect in a British cohort (n ¼ 319). 7 Although inconsistent findings may reflect differences in ethnic composition and other characteristics of patient populations, small sample sizes appear most problematic in the analyses of stratified patient groups (e.g., NR vs SR). Nonetheless, relatively simple hypotheses generated from these studies can be tested further in existing populations. Expanded search in new cohorts will be more time-consuming and require the effective communication and close cooperation between patients, clinicians, staff, laboratory investigators, and biostatisticians (Figure 2 ).
IMPLICATIONS OF PHARMACOGE-NETIC FINDINGS
The possible benefits from pharmacogenetic research are at least two-fold. First, consistent findings can guide more focused functional studies aimed at dissecting the intrinsic host-HCV interactions, especially those more beneficial to the host than the virus. Second, in the realm of clinical decision-making, informative genotyping can benefit patient care when genotypes clearly distinguish SRs from NRs. In the case of MX1 association, the predictive value of À88G/G genotype is rather limited (relative odds B2.0); clinicians thinking of withholding combination therapy in patients who carry this marker would inevitably struggle with the decision since onethird of patients with the À88G/G genotype can still respond to therapy. More likely, in À88G/G-positive patients whose therapy is well tolerated, it may be possible to prescribe higherdose regimens to increase efficacy. Supplementary therapy with interleukin-2 (IL-2), IFN-b, and protease inhibitor also provides valid alternatives.
At present, however, application of genotyping and confidential counseling remains only a theoretical option. Given the complexity and redundancy of genes involved in the immune response pathways, a single SNP like MX1 À88G4T is unlikely to account for the wide racial and individual disparities in response to HCV therapy. Even after additional factors are identified and confirmed through formal studies of representative cohorts, composite effects (additive, synergistic, independent, and antagonistic) of favorable and unfavorable markers coexisting in the same individuals (either by chance or by LD) will require systematic evaluation before a simple algorithm for capturing those effects can be incorporated into clinical practice. Moreover, the genetic profile will have to be considered in conjunction with nongenetic host factors including age, gender, BMI, duration of infection, hepatic pathology, and coinfection with other medically important agents, especially those that block the IFN-a signaling pathway or interfere with immune surveillance.
IMPORTANCE OF CONTINUING SYSTEMATIC STUDIES
Until an HCV vaccine or other reliable primary preventive measures become available, pharmacogenetic studies represent a worthwhile strategy to Figure 1 Major pharmacogenetic candidates in the IFN-response pathway. For systematic analyses, the pathway involves many genes with functionally important polymorphisms and mutations, of which several (underlined) have been studied in individual cohorts.
7-9 aR1a, IFN-a receptor 1, form a (full-length); aR2c, IFN-a receptor 2, form c (full-length); Tyk, tyrosine kinase; Jak, Janus kinase family; STAT, signal transducer and activator of transcription; -P, phosphorylation; p48, a 48-kDa polypeptide with DNA-binding property; MX, myxovirus resistance (IFN-a inducible GTPase); OAS, 2 0 -5 0 oligoadenylase synthetase; PKR, double-stranded RNA-dependent protein kinase.
Pharmacogenetics and HCV Infection J Tang and RA Kaslow follow toward control of HCV-related morbidity and mortality. To this end, study design and analytical strategies should require close attention to the inherent complexity of human genetics in general and the primary (ie IFNrelated) (Figure 1 ) and myriad secondary (other) immune and regulatory pathways in particular. For example, as persuasive as data on the MX1 À88 SNP may be, potential 'hitch-hiking' and reciprocal effects cannot be ruled out without detailed analyses of local and extended haplotypes. More importantly, the few loci (MX1, OSA1, and PRK) studied so far are only part of the IFN-mediated antiviral pathway ( Figure 1) ; other related genes are also rich in nucleotide polymorphisms (microsatellites and SNPs). Recognition of genetically determined STAT1 deficiency as one cause of impaired response to viral infection 16 justifies a broad exploration of genes involved in IFN-a signal transduction. Differential expression of multiple splicing variants of type I IFN receptors (IFNAR1 and IFNAR2) points to another avenue of inquiry, 17 whereas discovery of additional relevant genes can still take the field in other directions.
Finally, population heterogeneity (or stratification) can confound pharmacogenetic analyses because many SNPs and haplotypes are specific to subsets of mixed populations. Such stratification of genetic variants and clinical phenotypes may be a better explanation than causality for population-specific relationships. This phenomenon may extend to multiple genes and from one pathway to another. Evaluation of multiple populations, either separately or in aggregate, provides one solution to that problem. An ongoing, NIH-sponsored multicenter study (VIRAHEP-C) of HCV-infected European and African Americans has been designed to address racial disparities in response to HCV therapy. New and confirmatory findings emerging from this joint effort will, hopefully, demonstrate the value of pharmacogenetics in understanding HCV pathogenesis and improving management of HCV-related disease outcomes. Total > 2 years Figure 2 Timeline and key components in pharmacogenetic analyses of HCV patients. For studies involving new patients, the complete process should take at least 2 years. Several important components (in bold) have not been fully examined. IRB, institutional review board; BMI, body mass index; FCT, full-dose combination (IFN-a2b plus ribavirin) therapy, MFCT, modified FCT (peginterferon-a2b replaces IFNa2b); ALT, alanine aminotransferase; PBMC, peripheral blood mononuclear cells; SR, sustained responders; NR, non-responders; HWE, Hardy-Weinberg equilibrium; LD, linkage disequilibrium.
